Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients

Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM

Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting

Study shows the importance of including patient voices in treatment discussions for older cancer patients

Understanding the remaining unmet needs in a post ASCT NDMM setting

Approaches to risk stratification in high risk myeloma

Use of bispecifics and CAR T cells in South America

Tailored to fit: New approaches in transplant-ineligible NDMM

Advancements in minimal residual disease detection in myeloma

Novel biomarkers in myeloma: CTCs and cfDNA

New classification for identifying HR myeloma based on cytogenetic abnormalities

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM